Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study

Frederik Persson MD, DMSc1 | Thomas Nyström MD PhD2 | Marit E. Jørgensen MD PhD3 | Bendix Carstensen MSc1 | Hanne L. Gulseth MD PhD3 | Marcus Thuresson PhD4 | Peter Fenici MD PhD5 | David Nathanson MD PhD2 | Jan W. Eriksson MD PhD6 | Anna Norhammar MD PhD7,8 | Johan Bodegard MD PhD9 | Kåre I. Birkeland MD PhD3,10

1Steno Diabetes Centre, Copenhagen, Denmark
2Karolinska Institutet, Södersjukhuset, Stockholm, Sweden
3Oslo University Hospital, Oslo, Norway
4Statisticon AB, Uppsala, Sweden
5AstraZeneca, Cambridge, UK
6Uppsala University, Uppsala, Sweden
7Karolinska Institutet, Stockholm, Sweden
8Capio S:t Görans Hospital, Stockholm, Sweden
9AstraZeneca Nordic-Baltic, Oslo, Norway
10University of Oslo, Oslo, Norway

Correspondence
Dr Johan Bodegard, AstraZeneca Nordic-Baltic, 0601 Oslo, Norway.
Email: johan.bodegard@astrazeneca.com

Funding Information
This work was sponsored by AstraZeneca AB.

Aims: To compare the sodium-glucose-cotransporter-2 (SGLT-2) inhibitor dapagliflozin with dipeptidyl peptidase-4 (DPP-4) inhibitors with regard to risk associations with major adverse cardiovascular (CV) events (MACE; non-fatal myocardial infarction, non-fatal stroke or cardiovascular mortality), hospitalization for heart failure (HHF), atrial fibrillation and severe hypoglycaemia in patients with type 2 diabetes (T2D) in a real-world setting.

Methods: All patients with T2D prescribed glucose-lowering drugs (GLDs) during 2012 to 2015 were identified in nationwide registries in Denmark, Norway and Sweden. Patients were divided into two groups: new users of dapagliflozin and new users of DPP-4 inhibitors, matched 1:3 by propensity score, calculated by patient characteristics, comorbidities and drug treatment. Cox survival models were used to estimate hazard ratio (HR) per country separately, and a weighted average was calculated.

Results: After matching, a total of 40 908 patients with T2D were identified as new users of dapagliflozin (n = 10 227) or a DPP-4 inhibitor (n = 30 681). The groups were well balanced at baseline; their mean age was 61 years and 23% had CV disease. The mean follow-up time was 0.95 years, with a total of 38 760 patient-years. Dapagliflozin was associated with a lower risk of MACE, HHF and all-cause mortality compared with DPP-4 inhibitors: HRs 0.79 (95% confidence interval [CI] 0.67-0.94), 0.62 (95% CI 0.50-0.77), and 0.59 (95% CI 0.49-0.72), respectively. Numerically lower, but non-significant HRs were observed for myocardial infarction (0.91 [95% CI 0.72-1.16]), stroke (0.79 [95% CI 0.61-1.03]) and CV mortality (0.76 [95% CI 0.53-1.08]). Neutral associations with atrial fibrillation and severe hypoglycaemia were observed.

Conclusions: Dapagliflozin was associated with lower risks of CV events and all-cause mortality compared with DPP-4 inhibitors in a real-world clinical setting and a broad T2D population.

KEYWORDS
cardiovascular disease, dapagliflozin, diabetes complications, DPP-4 inhibitor, hypoglycaemia, type 2 diabetes
1 | INTRODUCTION

Despite modern preventive treatment for cardiovascular (CV) complications, patients with type 2 diabetes (T2D) have an increased risk of mortality, heart failure and CV disease.1,2 The sodium glucose-co-transporter-2 (SGLT-2) inhibitors empagliflozin and canagliflozin have recently been shown to be associated with a reduced risk of CV disease and hospitalization for heart failure (HHF) and, in the case of empagliflozin, also a reduced risk of all-cause mortality, compared with placebo added to existing glucose-lowering drug (GLD) treatment in patients with T2D with high CV disease risk profile.3,4 As part of the CVD-REAL study programme designed to study the effects of SGLT-2 inhibitor treatment on CV outcomes in a real-world setting,5,6 the CVD-REAL Nordic Study, a large multinational observational study of >90 000 patients with T2D, has suggested the presence of SGLT-2 inhibitor class effects by showing lower risk of CV mortality, major adverse CV events (MACE; non-fatal myocardial infarction, non-fatal stroke or CV mortality) and HHF compared with other GLDs;7 however, the comparator group used in that study,7 other GLDs, consisted of almost 50% patients with T2D treated with insulin or sulphonylureas, which have been shown to have increased associated CV risks compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in previous observational studies.8–15 In addition, it is not fully clear to what extent this could have influenced the risk estimates. Moreover, the comparator group other GLDs does not reflect any particular GLD class but rather the real-world use of GLDs in patients with T2D, similarly to new use of a SGLT-2 inhibitor. It is therefore very important to assess CV risks by comparing SGLT-2 inhibitor treatment with a specific and clinically relevant treatment strategy, for example, DPP-4 inhibitor therapy. To the best of our knowledge, such an analysis has not been reported before and there are no ongoing CV outcome trials comparing SGLT-2 with DPP-4 inhibitor treatment.

The DPP-4 inhibitors belong to a class of widely used GLDs, which have been shown to be associated with CV safety in several large clinical trials, although concerns about increased heart failure risk have been raised.16–18 Being a widely used modern oral treatment for T2D, as is SGLT-2 inhibitor treatment, DPP-4 inhibitors are a well-suited comparator for examining the effectiveness of another GLD. Moreover, for second- or higher line therapy for patients with T2D, both SGLT-2 inhibitors and DPP-4 inhibitors are recommended treatment strategies.19

The primary aim of the present study was to investigate if dapagliflozin, the most frequently used SGLT-2 inhibitor in the Nordic countries,7 was associated with risks of MACE, HHF and all-cause mortality compared with DPP-4 inhibitors in a broad unselected population with T2D using nationwide data from Denmark, Norway and Sweden. Secondary aims were to study unstable angina, atrial fibrillation and severe hypoglycaemia.

2 | MATERIALS AND METHODS

2.1 | Data sources

The three Nordic countries Denmark, Norway and Sweden have comprehensive, nationwide public healthcare systems. All citizens have a unique personal identification number (person-ID), which is mandatory for all administrative purposes (including any contact with the healthcare system and drug purchases), thus providing a complete full population medical history. In the present study, we used data from Prescribed Drug Registers, the Cause of Death Registers, and the National Patient Registers covering all hospitalizations with discharge diagnoses and all outpatient hospital visits. Individual patient-level data from the national registers were linked using the person-ID. The linked databases were managed separately by the Steno Diabetes Centre Copenhagen, Gentofte, Denmark (Danish database) and Statisticon AB, Uppsala, Sweden (Swedish and Norwegian databases). Anonymized data were used and analyses were performed within each separate country database (for detailed country-specific database information, see Supporting Information Appendix S1 - section 1). The separate studies were approved accordingly by the Danish Data Protection Agency (Datatilsynet, registration number 2015-41-4148), the Norwegian Data Protection Agency (registration number 16/00005-2/GRA) and Regional Committee for Medical and Health Research Ethics South East (registration number 2015/1337/REK), and the Stockholm regional ethics committee (registration number 2013/2206-31).

2.2 | Study population

All patients with T2D aged ≥18 years who were new drug users of either dapagliflozin or DPP-4 inhibitors during the years 2012 to 2015, when dapagliflozin was available in all three countries, were eligible for inclusion (Supporting Information Table S1A). Patients with type 1 diabetes, gestational diabetes and polycystic ovarian syndrome were excluded (Supporting Information Appendix S1 - section 2). A new user date was defined as the date on which the drug class of interest was dispensed, preceded by a 12-month period with no dispensing of the same drug class. This definition allowed several possible new user dates for a patient within the observation period, both within drug class and between classes. In case multiple new user dates were found, the definition of an index date followed a hierarchical structure, starting with the dapagliflozin new user date if present.

2.3 | Baseline data

Patient characteristics included age at the date of index drug, sex, index date, date of first dispensing of a registered GLD, and a description of patient frailty (defined as at least 1 hospitalization of ≥3 consecutive days during the year prior to index date).1,13,14, detailed definitions are provided in Supporting Information Table S1B. Comorbidities were searched for in all available data prior to and including the index date, with the exceptions of severe hypoglycaemia (within 12 months prior to index date) and cancer (within 5 years prior to index date); detailed definitions are provided in Supporting Information Table S1C. ‘Prior’ medications were defined as any prescription 12 months prior to and including index date. Detailed definitions are provided in Supporting Information Table S1D.

2.4 | Follow-up

The primary analyses used an on-treatment approach. Patients were observed from index date until index drug discontinuation (defined as
the first gap of 6 months between filled prescriptions), death, or December 31, 2015. In addition, intention-to-treat analyses were performed also including the follow-up time after index treatment discontinuation.

2.5 | Definition of outcomes

Outcomes were: MACE, defined by main diagnosis of non-fatality myocardial infarction or non-fatal ischaemic/haemorrhagic stroke or CV mortality; HHF, defined by in- or outpatient visits with a main diagnosis of heart failure; all-cause mortality, defined as death from any cause; MACE+, MACE with the addition of unstable angina; and MACE++, MACE with the addition of unstable angina and HHF. Other predefined outcomes were atrial fibrillation and severe hypoglycaemia. Detailed outcome definitions are given in Supporting Information Table S1C.

2.6 | Propensity score matching

Propensity scores were used to match each patient who initiated dapagliflozin with patients who initiated a DPP-4 inhibitor (1:3 match, using a caliper of 0.2). The probability of having a new drug initiation of dapagliflozin was estimated using a logistic regression model with patient characteristics, age, time since first GLD initiation, comorbidity, coronary revascularization, frailty, and separate classes of GLDs, CV disease preventive drugs, drugs associated with treatment of heart failure, and date of both index drug and first-line initiation as independent variables. Detailed information on variables included in the propensity score are given in Supporting Information Tables S2A to C, S3A to C and Appendix S1 - section 3. The matching was performed using the Match function in the R package Matching.20

2.7 | Statistical analysis

Standardized differences of >10% were used to detect significant group imbalance between baseline variables.21 The primary analysis was a survival analysis using a Cox proportional hazards model, with time since index date as the underlying time scale. A risk reduction in the dapagliflozin group was considered to be significant when the P value was <.05 and the hazard ratio (HR) was <1. Proportional assumptions were tested. Pooled Kaplan–Meier plots from all 3 countries were used for descriptive purposes only.22 The primary model used only index drug as a covariate (dapagliflozin vs DPP-4 inhibitor). All analyses were conducted using R statistical software (R version 3.2.3).23

3 | RESULTS

3.1 | Unmatched patient characteristics and treatments

During the observation period years 2012 to 2015, 94 064 patients with T2D initiated new therapy with dapagliflozin or a DPP-4 inhibitor (Figure 1). Before matching, patients in the dapagliflozin group were younger, less frequently women, had more microvascular disease and a lower CV burden compared with patients in the DPP-4 inhibitor group (Supporting Information Table S2). The dapagliflozin and DPP-4 inhibitor group were similar with respect to CV disease preventive treatment, statins, antihypertensives and low-dose aspirin.

3.2 | Propensity score-matched analyses

After matching, a total of 40 908 patients with T2D could be included as new users of either dapagliflozin (n = 10 227) or a DPP-4 inhibitor (n = 30 681). The groups were well balanced at baseline: the mean age was 61 years, 40% were women, 23% had CV disease, 15% microvascular disease and 84% had been prescribed CV disease preventive drugs (Table 1). The mean follow-up time was 0.95 years (dapagliflozin 0.91 years and DPP-4 inhibitor 0.96 years), with a total of 38 760 patient-years.

3.3 | Cardiovascular disease

The dapagliflozin group was associated with a lower risk of MACE and HHF compared with the DPP-4 inhibitor group: HRs 0.79 (95% confidence interval [CI] 0.67-0.94) and 0.62 (0.50-0.77), respectively (Table 2 and Figure 2). The risk of non-fatal myocardial infarction, non-fatal stroke and CV mortality was non-significantly lower in the dapagliflozin group: HRs 0.91 (95% CI 0.72-1.16), 0.79 (95% CI 0.61-1.03), and 0.76 (95% CI 0.53-1.08), respectively. Lower HRs for MACE+ and MACE++ in the dapagliflozin group were observed: HRs 0.81 (95% CI 0.69-0.94) and 0.75 (95% CI 0.66-0.86), respectively. No associations were observed with unstable angina.

3.4 | Other outcomes

There was a lower HR for all-cause mortality (0.59 [95% CI 0.49-0.72]) in the dapagliflozin group compared with the DPP-4 inhibitor group (Table 2 and Figure 2). The dapagliflozin group showed neutral associations for atrial fibrillation and severe hypoglycaemia compared with DPP-4 inhibitor: HRs 0.92 (95% CI 0.76-1.12) and 0.94 (95% CI 0.74-1.19), respectively.

![FIGURE 1](image-url) Patient flow charts for dapagliflozin vs DPP-4 inhibitor groups. Proportion of patients not fulfilling propensity matching 1:3 with 0.2 caliper were excluded and are shown in grey boxes.
3.5 | Sensitivity analyses

When including time after treatment discontinuation (eg, intention-to-treat), the analysis showed similar risk associations between the dapagliflozin group and the DPP-4 inhibitor group (Supporting Information Table S4). Risk estimation for heart failure registered in-hospital only (ie, excluding outpatient events) remained unchanged compared with HHF, including both in- and outpatient events (Supporting Information Table S4).

4 | DISCUSSION

In this large population of >40 000 patients with T2D from 3 countries, covering ~20 million inhabitants, new use of dapagliflozin was associated with 21% lower risk of MACE and 38% lower risk of HHF compared with new use of DPP-4 inhibitors. In addition, a 41% lower all-cause mortality risk was observed. The MACE components, myocardial infarction, stroke and CV mortality, did separately show lower, but non-significant differences. Extended outcome combinations of MACE, adding unstable angina and HHF, respectively, did not change the lower risk associations with dapagliflozin compared with DPP-4 inhibitors. Neutral associations were found with severe hypoglycaemia and atrial fibrillation.

Similar to our reported 21% (HR 0.79 [95% CI 0.67-0.94]) associated lower risk of MACE, a recent meta-analysis of dapagliflozin treatment in patients with 30% established CV disease at baseline showed a numerically 23% (HR 0.77 [95% CI 0.54-1.10]) lower risk of MACE compared with placebo.24 Furthermore, the numerical risk reductions for MACE+ reported by the same meta-analysis also showed similarities with our results: HRs 0.79 (95% CI 0.58-1.07) and 0.81 (95% CI 0.69-0.94) respectively.24 Despite not being significant, these meta-analyses on MACE outcomes, indirectly provide clinical trial data support to our real-world results.

The EMPA-REG OUTCOME trial showed that empagliflozin reduced the risk of MACE, HHF, and all-cause mortality compared

| TABLE 1  | Baseline patient characteristics of propensity-matched new users of dapagliflozin vs new users of DPP-4 inhibitors in a population with T2D |
|----------|-----------------------------------------------------------------------------------------------------------------------------------|
|          | Dapagliflozin |
| N = 10 227 | DPP-4 inhibitor N = 30 681 | Standardized difference<sup>a</sup> |
| Age, years (s.d.) | 61 (11.1) | 60.8 (12.4) | 0.017 |
| Sex (Female) | 4196 (41.0) | 12 391 (40.4) | 0.011 |
| First GLD, years (s.d.) | 6.5 (4.1) | 6.5 (4.1) | 0.009 |
| CV disease | 2356 (23.0) | 6970 (22.7) | 0.006 |
| Myocardial infarction | 730 (7.1) | 2183 (7.1) | 0.001 |
| Stroke | 566 (5.5) | 1699 (5.5) | 0.000 |
| Unstable angina | 286 (2.8) | 900 (2.9) | 0.007 |
| Heart failure | 485 (4.7) | 1440 (4.7) | 0.002 |
| Atrial fibrillation | 879 (8.6) | 2549 (8.3) | 0.008 |
| Chronic kidney disease | 219 (2.1) | 626 (2.0) | 0.006 |
| Microvascular complications | 1497 (14.6) | 4449 (14.5) | 0.003 |
| Cancer | 850 (8.3) | 2624 (8.6) | 0.007 |
| Metformin | 8522 (83.3) | 25 705 (83.8) | 0.010 |
| Sulphonylurea | 2668 (26.1) | 7920 (25.8) | 0.005 |
| GLP-1RAs | 798 (7.8) | 2309 (7.5) | 0.008 |
| Thiazolidinediones | 148 (1.4) | 416 (1.4) | 0.006 |
| Insulin | 3105 (30.4) | 8920 (29.1) | 0.023 |
| Short-acting | 1124 (11.0) | 3307 (10.8) | 0.006 |
| Intermediate-acting | 1504 (14.7) | 4358 (14.2) | 0.012 |
| Premixed insulin | 813 (7.9) | 2350 (7.7) | 0.009 |
| Long-acting | 1044 (10.2) | 3062 (10.0) | 0.006 |
| CV disease preventive drugs | 8702 (85.1) | 26 041 (84.9) | 0.005 |
| Low-dose aspirin | 3497 (34.2) | 10 434 (34.0) | 0.003 |
| Statins | 6457 (63.1) | 19 405 (63.2) | 0.002 |
| Antihypertensives | 7483 (73.2) | 22 255 (72.5) | 0.012 |
| Loop diuretics | 1364 (13.3) | 4036 (13.2) | 0.004 |
| Aldosteron antagonists | 441 (4.3) | 1303 (4.2) | 0.003 |
| Warfarin | 527 (5.2) | 1530 (5.0) | 0.006 |
| Receptor P2Y12 antagonists | 471 (4.6) | 1351 (4.4) | 0.008 |

Abbreviations: GLP-1RA, glucagon-like peptide-1 receptor agonists; s.d., standard deviation. All numbers in parenthesis are percentages, unless stated otherwise.

<sup>a</sup> Standardized difference of >10% (>0.1) is considered to represent a non-negligible difference.
The groups were matched 1:3 using propensity scores based on age, sex, frailty (treatment.

This finding is of particular interest because it is more in line with the CANVAS trial results (HR 0.90 [95% CI 0.71–1.15]) and considers benefit in stroke rates that could be expected by a mild reduction in blood pressure. The seemingly discrepant findings between our results and those of the EMPA-REG OUTCOME trial could be attributable to chance and/or presence of a potential unknown confounding factor at baseline; however, the virtually identical baseline variables, similar risk estimates for other outcomes compared with the EMPA-REG OUTCOME and CANVAS trials\(^3,4\) and absent atrial fibrillation and hypoglycaemia associations all support our results.

Previous observational multi-country studies have recently shown that parts of the EMPA-REG OUTCOME and CANVAS trial results do translate to the SGLT-2 inhibitor class, and into a real-world setting with patients with T2D having broader CV risk profiles\(^3,4,6,7,30\); however, by using a wider range of outcomes, the present paper further adds to this knowledge base by showing that a specific SGLT-2 inhibitor, dapagliflozin, is associated with lower CV risk in a real-world setting compared with a widely used GLD class, DPP-4 inhibitors. Observational effectiveness studies cannot replace randomized clinical trials, but might prove to be an important complement to these, translating results to a broader and more generalized patient population in a real-world setting.\(^3\)

While awaiting more complete evidence, observational comparative effectiveness studies may increase the understanding of the SGLT-2 inhibitor treatment outcome effects; however, confounding, particularly confounding by indication, cannot be fully excluded in observational studies, and the large ongoing prospective trial DECLARE-TIMI 58 (clinicaltrials.gov, NCT01730534), including >17 000 patients with both low and high CV risk, will further elucidate dapagliflozin-specific findings.

The strengths of the present study include its population-based, nationwide and unselected real-world design, which provides high external validity and a large enough population to allow country-wise propensity score-matched analyses to be performed. The results were consistent across all 3 countries and across several subgroup

### TABLE 2: Weighted means of HRs in Denmark, Norway and Sweden for new users of dapagliflozin vs new users of DPP-4 inhibitors

| Event | Dapagliflozin N = 10 227 | DPP-4 inhibitor N = 30 681 | Weighted average estimates N = 40 908 |
|-------|--------------------------|-----------------------------|---------------------------------------|
|       | No. events | Events/100 patient-years | No. events | Events/100 patient-years | HR  | 95% CI | P  |
| MACE  | 177        | 1.86                      | 695        | 2.34                      | 0.79 | (0.67-0.94) | 0.006 |
| Non-fatal myocardial infarction | 87         | 0.91                      | 304        | 1.02                      | 0.91 | (0.72-1.16) | 0.445 |
| Non-fatal stroke | 69        | 0.72                      | 270        | 0.90                      | 0.79 | (0.61-1.03) | 0.086 |
| Cardiovascular mortality | 38         | 0.40                      | 160        | 0.53                      | 0.76 | (0.53-1.08) | 0.122 |
| HHF   | 95         | 0.99                      | 467        | 1.57                      | 0.62 | (0.50-0.77) | <0.001 |
| MACE+ | 202        | 2.12                      | 779        | 2.63                      | 0.81 | (0.69-0.94) | 0.007 |
| Unstable angina | 37         | 0.39                      | 107        | 0.36                      | 1.09 | (0.75-1.59) | 0.655 |
| MACE++ | 285       | 3.01                      | 1164       | 3.96                      | 0.75 | (0.66-0.86) | <0.001 |
| All-cause mortality | 120       | 1.03                      | 644        | 1.75                      | 0.59 | (0.49-0.72) | <0.001 |
| Atrial fibrillation | 140       | 1.47                      | 469        | 1.58                      | 0.92 | (0.76-1.12) | 0.414 |
| Severe hypoglycaemia | 91         | 0.95                      | 300        | 1.01                      | 0.94 | (0.74-1.19) | 0.618 |

The groups were matched 1:3 using propensity scores based on age, sex, frailty (≥ 3 days in hospital within 1 year prior to index) comorbidity and treatment.
analyses. In addition, national registers with full coverage for hospitalizations, filled drug prescriptions and cause of death were used in 3 countries with established and complete public healthcare systems. Because diagnostic accuracy can be challenging for HHF in registries, it is reassuring that CV diagnoses in Denmark, Norway and Sweden have high validity.\textsuperscript{32–36} Anticipated neutral associations with atrial fibrillation and severe hypoglycaemia confirms the balanced risk profile at baseline for the dapagliflozin and DPP-4 inhibitor groups.

Limitations of the study include the fact that the results are only representative of patients who have been initiated on SGLT-2 inhibitor treatment or who are similar with regard to available clinical variables and, therefore, cannot be extended to all patients with T2D. The present work has no information on laboratory measurements, lifestyle variables, primary healthcare data, or socio-economic data, and consequently there may be remaining confounding factors. The close matching on a large number of essential variables ensures that some confounding factors are controlled for, but even propensity score matching does not remedy all confounding; for example, residual confounding by indication. Further, there was no information on diabetes duration, therefore, we used a proxy for time since diagnosis by matching for age at index date, time since first registered GLD treatment and classes of GLD at baseline. Because dapagliflozin has only been on the market since 2012 the mean follow-up was short, ~1 year; however, in the EMPA-REG OUTCOME study, similar early effects to those of the present study have been observed, suggesting that the 1-year mean follow-up time might be sufficient. We did not examine safety, but recent reports have not identified any new safety signals with dapagliflozin.\textsuperscript{37,38} For Norway and Sweden, we had no

---

**FIGURE 2** Pooled Kaplan-Meier curves from all 3 countries and HRs comparing propensity score-matched 1:3 groups of new users of dapagliflozin vs DPP-4 inhibitor treatment for MACE (A), HHF (B) and all-cause mortality (C) [Correction added on 18 September 2017 after first online publication: The label in Figure 2 (C) was previously incorrect and has been amended in this version]
information on emigration, which could result in loss to follow-up. No information on immigration was available and some patients might have less comprehensive disease history; however, the on-treatment analyses used should minimize the effects of patients emigrating because they would be classified as discontinuing treatment. Furthermore, the results were consistent with those of Denmark, where migration information was included.

In conclusion, dapagliflozin, when compared with DPP-4 inhibitor treatment, was associated with a lower risk of MACE, heart failure and all-cause mortality in a real-world T2D population, where 23% had previously established CV disease. A large ongoing prospective dapagliflozin trial will further elucidate these findings.

ACKNOWLEDGEMENTS

We are grateful to Susanna Jerström and Helena Goike at AstraZeneca for logistic support and valuable comments on the manuscript. Urban Olsson, Statisticon AB, is acknowledged for database management. Data from the Norwegian Patient Register have been used in this publication. The interpretation and reporting of these data are the sole responsibility of the authors, and no endorsement by the Norwegian patient register is intended nor should be inferred. Norwegian data on cause of death were obtained from the Norwegian Cause of Death Registry.

Conflict of interest

F. P. reports having received research grants from AstraZeneca and Novartis and lecture fees from Novartis, Eli Lilly, MSD, AstraZeneca and Boehringer Ingelheim and having served as a consultant for Astra Zeneca, Amgen, Novo Nordisk and MSD. T. N. has received unrestricted grants from AstraZeneca and Novo Nordisk, and is on the national board of Novo Nordisk, Sanofi-Aventis, Eli Lilly and Boehringer Ingelheim. M. E. J. holds shares in Novo Nordisk and has received grants and lecture fees from Astra Zeneca. B. C. is a shareholder of Novo Nordisk. J. W. E. has received honoraria or research grants from AstraZeneca, Novo Nordisk, Bristol-Myers-Squibb, Sanofi and MSD. P. F. holds a full-time position at AstraZeneca. D. N. has received consultancy fees from Novo Nordisk, Astra Zeneca and Eli Lilly. M. T. is employed by an independent statistical consultant company, Statisticon AB, Uppsala, Sweden, for which AstraZeneca Nordic-Baltic is a client. H. L. G. reports honoraria from Sanofi, Novo Nordisk, Lilly, Boehringer Ingelheim. A. N. has honoraria from MSD, Astra Zeneca, Eli Lilly, Boehringer Ingelheim, Novo Nordisk. J. B. holds a full-time position at AstraZeneca as epidemiologist. K. I. B. reports grants to his institution from AstraZeneca for this study and for lectures and consulting from Novo Nordisk, Sanofi, Lilly, Boehringer Ingelheim and Merck Sharp & Dohme.

Author contributions

All authors participated in the research design. M. T. and B. C. performed the data management and statistical analyses after discussion with all authors. All authors participated in data interpretation and in writing the manuscript. All authors took final responsibility in the decision to submit for publication. All authors are guarantors of the manuscript.

REFERENCES

1. Norhammar A, Bodegard J, Nyström T, Thuresson M, Eriksson JW, Nathanson D. Incidence, prevalence and mortality of type 2 diabetes requiring glucose-lowering treatment, and associated risks of cardiovascular complications: a nationwide study in Sweden, 2006-2013. Diabetologia. 2016;59(8):1692–1701.
2. Tacred M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720–1732.
3. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017. https://doi.org/10.1056/NEJMoa1611925. [Epub ahead of print].
4. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
5. The CVD-REAL Investigators and Study Group. CVD-REAL: a multinational, retrospective, observational study in patients with type 2 diabetes mellitus who are initiating treatment with SGLT-2 inhibitor or another glucose-lowering drug. AstraZeneca; 2017. https://www.cvreale.com/. Accessed March 10, 2017.
6. Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. Circulation. 2017;136(3):249–259.
7. Birkeland KI, Jørgensen ME, Carstensen B, et al. Cardiovascular morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus initiation of other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017. https://doi.org/10.1016/S2213-8587(17)30258-9.
8. Ekstrom N, Svensson AM, Miftaraj M, et al. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register. Diabetes Obes Metab. 2016;18(10):990–998.
9. Holden SE, Jenkins-Jones S, Morgan CL, Schernthaner G, Currie CJ. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. Diabetes Obes Metab. 2015;17(4):350–362.
10. Mogensen UM, Andersson C, Fosbol EL, et al. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulfonylurea in type 2 diabetes mellitus—a retrospective nationwide study. Diabetes Obes Metab. 2014;16(10):1001–1008.
11. Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality. Diabetes Obes Metab. 2014;16(10):977–983.
12. Nyström T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Novel oral glucose-lowering drugs compared to insulin are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycemia in type 2 diabetes patients. Diabetes Obes Metab. 2017;19(6):831–841.
13. Eriksson JW, Bodegard J, Nathanson D, Thuresson M, Nyström T, Norhammar A. Sulfonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Res Clin Pract. 2016;117:39–47.
14. Nyström T, Bodegard J, Nathanson D. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is
associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. Diabetes Res Clin Pract. 2017;123:199–208.

15. Roumie CL, Greervy RA, Grijalva CG, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014;312(22):2288–2296.

16. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242.

17. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326.

18. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335.

19. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(7):1498–1508.

20. Sekhon J. Multivariate and propensity score matching software with automated balance optimization. J Stat Softw. 2011;7(4):1–52.

21. Normand LT, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol. 2001;54(4):387–398.

22. Andersen PK, Keiding N. Interpretability and importance of functional in competing risks and multistate models. Stat Med. 2012;31(11–12):1074–1088.

23. R Core Team. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2015.

24. Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol. 2016;15:37.

25. Bertoni AG, Hundle WG, Massing MW, Bonds DE, Burke GL, Goff DC Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care. 2004;27(3):699–703.

26. Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55(8):2154–2162.

27. Johansson I, Dahlstrom U, Edner M, Nasman P, Ryden L, Norhammar A. Prognostic implications of type 2 diabetes mellitus in ischemic and nonischemic heart failure. J Am Coll Cardiol. 2016;68(13):1404–1416.

28. Authors/Task Force M, Ryden L, Grant PJ, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035–3087.

29. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38(3):376–383.

30. Cavender MA, Norhammar A, Birkeland KI, et al. Hospitalization for heart failure and death in new users of SGLT2 inhibitors in patients with and without cardiovascular disease: CVD-REAL study. American Diabetes Association – 77th Annual Scientific Sessions; June 13, 2017; San Diego, CA. Abstract 377-OR.

31. Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence – what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–2297.

32. Ludvigsson JF, Anderson E, Ekboom et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.

33. Sundboll J, Adelborg K, Munch T, et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. BMJ Open. 2016;6(11):e012832.

34. Ingelsson E, Amlov J, Sundstrom J, Lind L. The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail. 2005;7(5):787–791.

35. Kummer T, Gislason GH, Kirk V, et al. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail. 2008;10(7):658–660.

36. Brynildsen J, Hoiseth AD, Nygard S, et al. Diagnostic accuracy for heart failure – data from the Akershus Cardiac Examination 2 Study. Tidsskr Nor Laegeforen. 2015;135(19):1738–1744.

37. Jabbour SA, Seufert J, Sheen AJ, Baily CJ, Karup C, Langkilde AM. Safety update on dapagliflozin (DAPA) across the phase 2b/3 clinical trial program. American Diabetes Association 77th Scientific Sessions; June 11, 2017; San Diego, CA, pp 1263-P.

38. Petrykiv S, Sjostrom CD, Greasley PJ, Xu J, Persson F, Heerspink HJL. Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol. 2017;12(5):751–759.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Persson F, Nyström T, Jørgensen ME, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes Metab. 2018;20:344–351. https://doi.org/10.1111/dom.13077